Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma

1. Powles, T.
2. Lackner, M.R.
3. Oudard, S.
4. Escudier, B.
5. Ralph, C.
6. Brown, J.E.
7. Hawkins, R.E.
8. Castellano, D.
9. Rini, B.I.
10. Staehler, M.D.
11. Ravaud, A.
12. Lin, W.
13. O'Keeffe, B.
14. Wang, Y.
15. Lu, S.
16. Spoerke, J.M.
17. Huw, L.-Y.
18. Byrtek, M.
19. Zhu, R.
20. Ware, J.A.
21. Motzer, R.J.